BioVarta 2025: Innovation with Intent, Closing the Loop from Science to Impact  

New Delhi: BioVarta 2025 was conceived as a conversation around biotechnology, bringing together individuals who have contributed to advancing innovation at different stages of the journey. Organized by Premas Biotech, the gathering convened a cross-section of leaders from science, healthcare, policy, manufacturing, investment, and entrepreneurship to reflect on how innovation can be enabled, supported, and translated into real-world impact.

The intent behind BioVarta was deliberate. Innovation does not progress through discovery alone. It advances when science is aligned with manufacturing, regulation, capital, and clinical application. Across the day, the discussions explored how these elements interact, how alignment can be strengthened, and how closing the loop between discovery and deployment is essential for delivering outcomes at scale.

Held in New Delhi on December 13, 2025, the day-long dialogue unfolded through a structured set of conversations spanning translation, frontier innovation, scale-up, investment, and clinical development. Participants represented different parts of the biotechnology value chain, but the common thread was clear. Innovation becomes real only when the ecosystem enables it.

Welcoming the participants, Dr. Prabuddha Kundu, Co-Founder and Managing Director of Premas Biotech, reflected on the evolution of India’s biotechnology sector and the need for tighter integration between discovery, manufacturing, regulation, and capital so that innovation reaches patients and populations.

 Where Discovery Meets Impact

The opening discussions focused on translation, where discovery meets impact. Prof. N. K. Arora, Chairperson of India’s National Immunization Technical Advisory Group and a senior public health and immunization leader, underscored that scientific excellence achieves meaning only when aligned with societal and healthcare outcomes. He emphasized the importance of institutional strength, regulator engagement, and GMP-aligned systems that support quality and scale, so that innovations move from research environments into real-world use.

Adding a macroeconomic lens, Dr. Prasenjit K. Basu, Founder and Chief Economist at REAL-economics.com, spoke about how long-term competitiveness in innovation depends not only on scientific depth but also on talent flows, global positioning, and sustained innovation infrastructure. He highlighted the importance of retaining and attracting scientific capability and aligning national ambition with long-term ecosystem capacity.

From the perspective of academic translation and entrepreneurship, Dr. Ashutosh Chilkoti, Professor, Biomedical Engineering at Duke University, discussed what it takes to move research from labs to real-world applications. The discussions highlighted the need for translational platforms, shared infrastructure, and supportive ecosystems that reduce barriers for early-stage innovation and enable long-horizon science to mature into scalable products.

Innovation Supported by the Value Chain

Innovation was also examined through the lens of the enabling value chain. Mr. T. L. Satyaprakash, Joint Secretary at the Department of Pharmaceuticals, shared a perspective on how scale-up is often constrained not by the absence of ideas, but by the readiness of systems around them. He spoke about the importance of manufacturing preparedness, cost structures, and process design, and highlighted the role of automation, digitalisation, and optimized workflows in enabling GMP-compliant and economically viable scale-up. His reflections reinforced that innovation needs coordinated support across discovery, manufacturing, and market realities.

Innovations at the Cutting Edge

The discussions then broadened to frontier innovation and next-generation platforms. Drawing from her experience in national public health and disease surveillance systems, Dr. Nivedita Gupta, Scientist-G and Head of Communicable Diseases Division at ICMR, spoke about innovation as the ability to anticipate emerging challenges and strengthen readiness frameworks in advance. She emphasized the value of coordinated approaches, clear pathways, and standardized protocols in enabling faster, more reliable responses. Integrated frameworks such as One Health were discussed as forward-looking mechanisms for innovation across surveillance, diagnostics, and response planning. 

Prof. Samir Mitragotri, Hiller Professor and Core Faculty at Harvard University and the Wyss Institute, emphasized that innovation is incomplete until the loop is closed from science to outcomes. Drawing from his experience translating research into clinical and commercial products, he spoke about designing with scalability, manufacturability, and simplicity in mind. He highlighted that academic innovation can be a powerful engine for progress when paired with rigorous evaluation and purposeful translation pathways.

From a systems and execution lens, Mr. Jasdeep Singh Dhanoa, former Chief Information Officer of the Indian Navy, discussed disciplined execution and the importance of transparency when applying complex technologies such as artificial intelligence in high-stakes contexts. The discussion emphasized that innovation in deep-tech domains must be implemented thoughtfully, with interdisciplinary collaboration, clarity, and governance. 

Scaling Science and Informed Risk

As the dialogue moved toward scaling science, attention turned to informed risk-taking and the conditions needed for ideas to become scalable solutions. Dr. Sagar Sengupta, Director at BRIC–National Institute of Biomedical Genomics and Director (Additional Charge) at the National Brain Research Centre, spoke about the importance of sustained investment in foundational research and stronger collaboration between research institutions and industry to accelerate translation.

Prof. Anil Koul, Adjunct Professor at the London School of Hygiene and Tropical Medicine and Group Chief Scientific Officer at BSV/Mankind Pharma, known for work that has shaped global tuberculosis innovation, reflected on the journey from discovery to impact. Discussions highlighted how breakthrough outcomes require rigorous science, long-horizon persistence, and informed, calibrated risk-taking, alongside systems that support quality, affordability, and scale.

Capital, Platforms, and Ecosystem Enablement

Investment and ecosystem perspectives reinforced that innovation does not advance in isolation. Dr. Shirshendu Mukherjee, Managing Director at the Wadhwani Foundation, spoke about institutional platforms, innovation ecosystems, and how structured support can help move ideas toward execution. Mr. Uday Chatterjee, Angel Investor, discussed early-stage capital, founder support, and the realities of enabling innovation journeys through funding and mentorship.

Dr. Ashutosh Khanna, Associate Professor – Strategy and General Management at IMI New Delhi, contributed a strategy and systems view, emphasizing that scientific breakthroughs translate effectively only when organizational design, talent alignment, and execution frameworks are intentionally built around them.

A panel on Innovation and Indigenisation featured Mr. Praveen Gupta, Managing Director at Premal Lifesciences; Dr. Venkataramanan, CEO of Karkinos Healthcare; Dr. Jayanta Bhattacharya, Dean at THSTI; and Dr. Jagadeesh Bhat of Gangagen Biotechnology. The panel discussed strengthening domestic capabilities while building globally competitive enterprises, emphasizing that indigenisation is most powerful when paired with high standards, collaboration, and export-grade ambition.

Clinical Development, Bridging Bench to Bedside

The final technical discussions focused on clinical development and the opportunities while bridging bench to bedside. Dr. Gautam Sanyal, Founder of Vaccine Analytics, LLC and a global expert in vaccine process science and analytics, discussed the importance of rigorous characterization and process understanding in translating platforms to real-world use.

Dr. Dhananjay Patankar, Consultant and a seasoned biopharmaceutical CMC and GMP expert with decades of leadership experience in pharmaceutical and biologics development, spoke about translation realities across development, scale-up, and quality expectations. Dr. Dinesh Kundu, CEO, CO-Founder East Ocyon Bio, representing India’s startup ecosystem, shared perspectives from the innovation frontlines where scientific ambition must be matched with manufacturability, regulatory readiness, and practical scalability.

Summing up the dialogue, Dr. Prabuddha Kundu noted that India’s biotechnology ecosystem stands at a pivotal moment, supported by strong science, growing clinical capability, and an increasingly ambitious entrepreneurial base. He emphasized that tighter integration across discovery, manufacturing, regulation, and capital is essential so that innovation does not remain confined to the lab, but reaches patients at scale.

By the close of the day, a shared understanding had emerged. Innovation is not a single breakthrough or a solitary effort, but a continuum that spans science, systems, and people.

BioVarta 2025 created a space where these perspectives converged, enabling a diverse set of stakeholders to recognize the common thread connecting their work and the conditions required to close the loop from science to outcomes.